Counting and classifying inflammatory cells in uveitis with OCT
Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography
This project will try to use high-resolution OCT scans to count and categorize inflammatory cells and proteins in people with anterior uveitis and related eye inflammation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 5 Years to 85 Years |
| Sex | All |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT07065747 on ClinicalTrials.gov |
What this trial studies
This observational project uses high-resolution optical coherence tomography (OCT) scans to detect and quantify inflammatory cells and proteins in eyes with anterior uveitis and related conditions. Participants include eyes with active inflammation from causes such as HLA-B27-associated uveitis, JIA, HSV, Birdshot, Behcet, sarcoidosis, a posterior vitreous detachment group with floaters, and healthy control eyes. Imaging from these groups will be compared to develop an unbiased, standardized method for counting and classifying cellular and protein findings on OCT. The study excludes people who cannot give consent, maintain stable fixation for imaging, commit to required visits, or who are pregnant or breastfeeding.
Who should consider this trial
Good fit: Ideal candidates are people with active intraocular inflammation from the listed causes (e.g., HLA-B27 uveitis, JIA-associated uveitis, HSV, Birdshot, Behcet, sarcoidosis), individuals with PVD and floaters, or healthy volunteers without prior uveitis or eye surgery.
Not a fit: People who cannot give informed consent, cannot maintain steady fixation for OCT imaging, cannot attend required visits, or who are pregnant or breastfeeding are not suitable and would likely not benefit from participation.
Why it matters
Potential benefit: If successful, this could provide an objective, noninvasive way to monitor eye inflammation and guide treatment decisions more precisely.
How similar studies have performed: Prior research has shown OCT can visualize inflammatory cells and vitreous changes, but standardized, automated counting and classification methods remain exploratory.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis/HLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade. 2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD). 3. Healthy/Control Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery. Exclusion Criteria: 1. Inability to give informed consent. 2. Inability to maintain stable fixation for OCT imaging. 3. Inability to commit to required visits to complete the study. 4. Pregnancy and breastfeeding.
Where this trial is running
Portland, Oregon
- Casey Eye Institute - Oregon Health & Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Yan Li, PhD — Oregon Health and Science University
- Study coordinator: Humberto Martinez, COT, MBA
- Email: martinhu@ohsu.edu
- Phone: 503-494-7712
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.